← Evidence map

ArticleBlood advances2026

CAR-T therapy is the preferred option in relapsed/refractory multiple myeloma.

Rahul BanerjeePubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 41973829